{"protocolSection": {"identificationModule": {"nctId": "NCT00713830", "orgStudyIdInfo": {"id": "EFC6015"}, "secondaryIdInfos": [{"id": "EudraCT 2007-005881-11"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea", "acronym": "GETGOAL-S"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-07-10", "studyFirstSubmitQcDate": "2008-07-10", "studyFirstPostDateStruct": {"date": "2008-07-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-08-18", "resultsFirstSubmitQcDate": "2016-10-21", "resultsFirstPostDateStruct": {"date": "2016-12-14", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-02-21", "dispFirstSubmitQcDate": "2012-02-21", "dispFirstPostDateStruct": {"date": "2012-02-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-21", "lastUpdatePostDateStruct": {"date": "2016-12-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide when added to sulfonylurea with or without metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than (\\<) 7 percent (%); percentage of patients reaching HbA1c less than or equal to (\\<=) 6.5%; body weight; fasting plasma glucose (FPG); beta-cell function assessed by homeostasis model assessment (HOMA) beta; 2-hour postprandial plasma glucose (PPG), glucagon, insulin, proinsulin, and C-peptide after a standardized meal challenge test in a sub-study in all patients in selected centers; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.", "detailedDescription": "Patients who complete the 24-week main double-blind treatment would undergo a variable double-blind extension treatment, which ends for all patients at approximately the scheduled date of Week 76 visit (Visit 25) for the last randomized patient."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["hyperglycemia, GLP-1"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 859, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lixisenatide", "type": "EXPERIMENTAL", "description": "2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Device: Pen auto-injector", "Drug: Sulfonylurea", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.", "interventionNames": ["Drug: Placebo", "Device: Pen auto-injector", "Drug: Sulfonylurea", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Lixisenatide (AVE0010)", "description": "Self administered by subcutaneous injections once daily within the hour preceding breakfast.", "armGroupLabels": ["Lixisenatide"]}, {"type": "DRUG", "name": "Placebo", "description": "Self administered by subcutaneous injections once daily within the hour preceding breakfast.", "armGroupLabels": ["Placebo"]}, {"type": "DEVICE", "name": "Pen auto-injector", "armGroupLabels": ["Lixisenatide", "Placebo"], "otherNames": ["OptiClik\u00ae"]}, {"type": "DRUG", "name": "Sulfonylurea", "description": "Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.", "armGroupLabels": ["Lixisenatide", "Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin if given to be continued at stable dose (at least 1.5 gram per day \\[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\\]) up to the end of treatment.", "armGroupLabels": ["Lixisenatide", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-Treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG blood sample was drawn 2 hours after start of a standardized meal (standardized meal challenge test performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Beta-cell Function Assessed by HOMA-beta at Week 24", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta blood samples were drawn during a standardized meal challenge test (performed in selected sites). HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (FPG \\[mmol/L\\] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Glucagon and 2-hour Postprandial Glucagon at Week 24", "description": "The fasting glucagon and the 2-hour postprandial glucagon blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Insulin (FPI) and 2-hour Postprandial Plasma Insulin at Week 24", "description": "The fasting plasma insulin and the 2-hour postprandial plasma insulin blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Proinsulin and 2-hour Postprandial Proinsulin at Week 24", "description": "The fasting Proinsulin and the 2-hour postprandial Proinsulin blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting C-peptide and 2-hour Postprandial C-peptide at Week 24", "description": "The fasting C-peptide and the 2-hour postprandial C-peptide blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline up to Week 24"}], "otherOutcomes": [{"measure": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test (performed in selected sites), before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Proinsulin-to-insulin Ratio and 2-hour Postprandial Proinsulin-to-insulin Ratio at Week 24", "description": "The fasting proinsulin-to-insulin ratio and 2-hour postprandial proinsulin-to-insulin ratio were measured during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 120 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with a sulfonylurea alone or a sulfonylurea in association with metformin\n\nExclusion Criteria:\n\n* HbA1c less than (\\<) 7% or greater than (\\>) 10% at screening\n* At the time of screening age less than legal age of majority\n* Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method\n* Type 1 diabetes mellitus\n* Sulfonylurea less than the maximum effective dose according to local labeling\n* Sulfonylurea not at a stable (unchanged) dose for at least 3 months prior to screening\n* In case of treatment with metformin in association with sulfonylurea, no stable (unchanged) treatment with metformin of at least 1.5 gram per day (except at least 0.75 gram per day in Japan and at least 1.0 gram per day in South Korea), for at least 3 months prior to screening visit\n* FPG at screening \\>250 milligram per deciliter (mg/dL) (\\>13.9 millimole per liter \\[mmol/L\\])\n* History of hypoglycemia unawareness\n* Body mass index less than or equal to (\\<=) 20 kilogram per square meter (kg/m\\^2)\n* Weight change of \\>5 kg during the 3 months preceding the screening visit\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease\n* History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening\n* Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening\n* Within the last 6 months prior to screening, history of myocardial infarction, stroke, or heart failure requiring hospitalization\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening\n* Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period\n* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure (SBP) or diastolic blood pressure (DBP) \\>180 millimeter of mercury (mmHg) or \\>95 mmHg, respectively\n* Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: \\>2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: \\>3 times ULN; total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin \\<11 gram/deciliter and/or neutrophils \\<1500 per cubic millimeter (mm\\^3) and/or platelets \\<100 000/mm\\^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody\n* Any clinically significant abnormality identified on physical examination, laboratory tests or vital signs at the time of screening that in the judgment of the Investigator or any sub investigator precludes safe completion of the study or constrains efficacy assessment\n* Patients who are considered by the Investigator or any sub investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, Investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)\n* Patients with condition/concomitant diseases making them non-evaluable for the efficacy assessment\n* Use of oral or injectable antidiabetic or hypoglycemic agents other than sulfonylurea and metformin (for example, alpha glucosidase inhibitor, thiazolidinedione, rimonabant, exenatide, dipeptidyl-peptidase 4 (DPP-4) inhibitors, insulin) within 3 months prior to the time of screening\n* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening\n* Use of any investigational drug within 3 months prior to study\n* Any previous treatment with lixisenatide (for example, participation in a previous study with lixisenatide)\n* Renal impairment defined with serum creatinine \\>1.4 mg/dL in women and serum creatinine \\>1.5 mg/dL in men (applicable only for patients with metformin treatment)\n* End-stage renal disease as defined by a serum creatinine clearance of \\<15 milliliter/minute (calculated by the Cockcroft and Gault formula) and/or patients on dialysis (if no treatment with metformin)\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening\n* Allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol\n* Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in phase (\\>2 injections missed); and patient with any adverse event which precludes the inclusion in the study, as assessed by the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Cairo", "country": "Egypt", "geoPoint": {"lat": 30.06263, "lon": 31.24967}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Mumbai", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Natanya", "country": "Israel"}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Gouda", "country": "Netherlands", "geoPoint": {"lat": 52.01667, "lon": 4.70833}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bucuresti", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Megrine", "country": "Tunisia", "geoPoint": {"lat": 36.76917, "lon": 10.23639}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}]}, "referencesModule": {"references": [{"pmid": "24650952", "type": "RESULT", "citation": "Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications. 2014 May-Jun;28(3):386-92. doi: 10.1016/j.jdiacomp.2014.01.012. Epub 2014 Jan 28."}, {"pmid": "27319011", "type": "DERIVED", "citation": "Ahren B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Sep;7(3):583-90. doi: 10.1007/s13300-016-0179-6. Epub 2016 Jun 18."}, {"pmid": "27267268", "type": "DERIVED", "citation": "Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, Gonzalez-Galvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahren B. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse beta-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016 Sep-Oct;30(7):1385-92. doi: 10.1016/j.jdiacomp.2016.05.018. Epub 2016 May 24."}, {"pmid": "27252787", "type": "DERIVED", "citation": "Seino H, Onishi Y, Naito Y, Komatsu M. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016 Jun 1;8:36. doi: 10.1186/s13098-016-0151-7. eCollection 2016."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 1438 participants were screened of which 579 (40.3%) were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7% and less than or equal to 10%). A total of 859 participants were randomized.", "recruitmentDetails": "The study was conducted at 136 centers in 16 countries between July 08, 2008 and January 14, 2011. The overall duration of treatment was at least 76 weeks (24 weeks main double-blind treatment; variable double-blind extension treatment).", "groups": [{"id": "FG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "FG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized.", "numSubjects": "286"}, {"groupId": "FG001", "numSubjects": "573"}]}, {"type": "Modified Intent-to-Treat(mITT)Population", "achievements": [{"groupId": "FG000", "comment": "All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.", "numSubjects": "286"}, {"groupId": "FG001", "numSubjects": "570"}]}, {"type": "Safety Population", "achievements": [{"groupId": "FG000", "comment": "All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.", "numSubjects": "285"}, {"groupId": "FG001", "comment": "1 patient randomized to placebo received Lixisenatide (at least one dose)", "numSubjects": "574"}]}, {"type": "Subgroup for Standardized Meal Test", "achievements": [{"groupId": "FG000", "comment": "Patients at selected sites where standardized meal challenge test was performed.", "numSubjects": "155"}, {"groupId": "FG001", "numSubjects": "313"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "204"}, {"groupId": "FG001", "numSubjects": "396"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "177"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "71"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Poor Compliance to Protocol", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "Familial and Personal Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "34"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "10"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.The one patient in the placebo group who received Lixisenatide was described in the Lixisenatide group.", "groups": [{"id": "BG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "BG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "285"}, {"groupId": "BG001", "value": "574"}, {"groupId": "BG002", "value": "859"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.8", "spread": "10.1"}, {"groupId": "BG001", "value": "57.0", "spread": "9.8"}, {"groupId": "BG002", "value": "57.2", "spread": "9.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "290"}, {"groupId": "BG002", "value": "425"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "284"}, {"groupId": "BG002", "value": "434"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Race: Caucasian/White", "categories": [{"measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "297"}, {"groupId": "BG002", "value": "448"}]}]}, {"title": "Race: Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "26"}]}]}, {"title": "Race: Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "125"}, {"groupId": "BG001", "value": "260"}, {"groupId": "BG002", "value": "385"}]}]}, {"title": "Ethnicity: Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "23"}]}]}, {"title": "Ethnicity: Non Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "280"}, {"groupId": "BG001", "value": "556"}, {"groupId": "BG002", "value": "836"}]}]}]}, {"title": "Glycosylated Hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.21", "spread": "0.84"}, {"groupId": "BG001", "value": "8.28", "spread": "0.86"}, {"groupId": "BG002", "value": "8.25", "spread": "0.85"}]}]}]}, {"title": "2-Hour Postprandial Plasma Glucose (PPG)", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Number of patients analyzed = 154 and 309 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "millimole per liter (mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.44", "spread": "3.74"}, {"groupId": "BG001", "value": "16.69", "spread": "4.02"}, {"groupId": "BG002", "value": "16.60", "spread": "3.92"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.29", "spread": "2.37"}, {"groupId": "BG001", "value": "9.67", "spread": "2.24"}, {"groupId": "BG002", "value": "9.55", "spread": "2.29"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "84.42", "spread": "22.83"}, {"groupId": "BG001", "value": "82.30", "spread": "21.76"}, {"groupId": "BG002", "value": "83.00", "spread": "22.13"}]}]}]}, {"title": "Homeostasis Model Assessment for Beta-cell Function (HOMA-beta)", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta (percentage \\[%\\] of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (FPG \\[mmol/L\\] minus 3.5). Number of patients analyzed = 152 and 306 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of normal beta cells function", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.43", "spread": "39.43"}, {"groupId": "BG001", "value": "34.28", "spread": "69.82"}, {"groupId": "BG002", "value": "34.99", "spread": "61.39"}]}]}]}, {"title": "Fasting glucagon", "description": "Number of patients analyzed = 152 and 309 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nanogram per liter (ng/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.89", "spread": "0.55"}, {"groupId": "BG001", "value": "0.83", "spread": "0.43"}, {"groupId": "BG002", "value": "0.85", "spread": "0.47"}]}]}]}, {"title": "2-hour postprandial glucagon", "description": "Number of patients analyzed = 149 and 300 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "102.27", "spread": "39.37"}, {"groupId": "BG001", "value": "97.83", "spread": "31.94"}, {"groupId": "BG002", "value": "99.31", "spread": "34.60"}]}]}]}, {"title": "Fasting plasma insulin (FPI)", "description": "Number of patients analyzed = 152 and 306 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "picomole per liter (pmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.89", "spread": "63.92"}, {"groupId": "BG001", "value": "61.34", "spread": "52.63"}, {"groupId": "BG002", "value": "63.18", "spread": "56.61"}]}]}]}, {"title": "2-hour postprandial plasma insulin", "description": "Number of patients analyzed = 154 and 305 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "281.26", "spread": "243.56"}, {"groupId": "BG001", "value": "259.44", "spread": "182.64"}, {"groupId": "BG002", "value": "266.76", "spread": "205.09"}]}]}]}, {"title": "Fasting proinsulin", "description": "Number of patients analyzed = 138 and 290 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.39", "spread": "32.61"}, {"groupId": "BG001", "value": "33.35", "spread": "27.43"}, {"groupId": "BG002", "value": "33.69", "spread": "29.17"}]}]}]}, {"title": "2-hour postprandial proinsulin", "description": "Number of patients analyzed = 130 and 257 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.73", "spread": "46.48"}, {"groupId": "BG001", "value": "62.12", "spread": "44.80"}, {"groupId": "BG002", "value": "61.99", "spread": "45.31"}]}]}]}, {"title": "Fasting C-peptide", "description": "Number of patients analyzed = 152 and 309 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.89", "spread": "0.55"}, {"groupId": "BG001", "value": "0.83", "spread": "0.43"}, {"groupId": "BG002", "value": "0.85", "spread": "0.47"}]}]}]}, {"title": "2-hour postprandial C-peptide", "description": "Number of patients analyzed = 152 and 308 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.12", "spread": "1.05"}, {"groupId": "BG001", "value": "1.99", "spread": "0.90"}, {"groupId": "BG002", "value": "2.03", "spread": "0.95"}]}]}]}, {"title": "Glucose Excursion", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the meal test, before study drug administration. Number of patients analyzed = 154 and 309 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.84", "spread": "3.78"}, {"groupId": "BG001", "value": "6.99", "spread": "3.71"}, {"groupId": "BG002", "value": "6.94", "spread": "3.73"}]}]}]}, {"title": "Fasting proinsulin-to-insulin ratio", "description": "Number of patients analyzed = 137 and 285 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.62", "spread": "0.36"}, {"groupId": "BG001", "value": "0.70", "spread": "0.57"}, {"groupId": "BG002", "value": "0.67", "spread": "0.51"}]}]}]}, {"title": "2-hour postprandial proinsulin-to-insulin ratio", "description": "Number of patients analyzed = 130 and 253 for Placebo and Lixisenatide treatment arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.30", "spread": "0.22"}, {"groupId": "BG001", "value": "0.32", "spread": "0.24"}, {"groupId": "BG002", "value": "0.31", "spread": "0.23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-Treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.071"}, {"groupId": "OG001", "value": "-0.85", "spread": "0.061"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To detect a difference of 0.5% (or 0.4%) in change from baseline to Week 24 in HbA1c between lixisenatide and placebo, 570 patients in lixisenatide arm and 285 in placebo arm would provide a power of 99% (or 98%) assuming common standard deviation of 1.3% with a 2-sided test at 5% significance level.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (\\<8.0, \\>=8.0%), metformin use (yes, no), country as fixed effects, baseline HbA1c as covariate.", "statisticalMethod": "ANCOVA", "paramType": "Least squares (LS) mean difference", "paramValue": "-0.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.867", "ciUpperLimit": "-0.621", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.063"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG blood sample was drawn 2 hours after start of a standardized meal (standardized meal challenge test performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 2-hour PPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.489"}, {"groupId": "OG001", "value": "-6.19", "spread": "0.408"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "283"}, {"groupId": "OG001", "value": "564"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "0.161"}, {"groupId": "OG001", "value": "-0.99", "spread": "0.139"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "554"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "spread": "0.234"}, {"groupId": "OG001", "value": "-1.76", "spread": "0.202"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Beta-cell Function Assessed by HOMA-beta at Week 24", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta blood samples were drawn during a standardized meal challenge test (performed in selected sites). HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (FPG \\[mmol/L\\] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HOMA-beta assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% of normal beta cells function", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "241"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.63", "spread": "5.663"}, {"groupId": "OG001", "value": "4.83", "spread": "4.686"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test (performed in selected sites), before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucose excursion assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "spread": "0.432"}, {"groupId": "OG001", "value": "-5.22", "spread": "0.360"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Glucagon and 2-hour Postprandial Glucagon at Week 24", "description": "The fasting glucagon and the 2-hour postprandial glucagon blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period and 'n' = patients with baseline and at least 1 post-baseline assessment for the specified category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "238"}]}], "classes": [{"title": "Fasting glucagon (n=111, 238)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.03", "spread": "2.566"}, {"groupId": "OG001", "value": "-2.10", "spread": "2.081"}]}]}, {"title": "2-hour postprandial glucagon (n=114, 234)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.19", "spread": "2.999"}, {"groupId": "OG001", "value": "-23.33", "spread": "2.500"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Insulin (FPI) and 2-hour Postprandial Plasma Insulin at Week 24", "description": "The fasting plasma insulin and the 2-hour postprandial plasma insulin blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline plasma insulin assessment during on-treatment period and 'n' = patients with baseline and at least 1 post-baseline assessment for the specified category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "244"}]}], "classes": [{"title": "FPI (n=117, 242)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.42", "spread": "6.587"}, {"groupId": "OG001", "value": "-4.03", "spread": "5.445"}]}]}, {"title": "2-hour postprandial plasma insulin (n=120, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.22", "spread": "18.754"}, {"groupId": "OG001", "value": "-67.67", "spread": "15.944"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Proinsulin and 2-hour Postprandial Proinsulin at Week 24", "description": "The fasting Proinsulin and the 2-hour postprandial Proinsulin blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period and 'n' = patients with baseline and at least 1 post-baseline assessment for the specified category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"title": "Fasting proinsulin (n=97, 205)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "1.983"}, {"groupId": "OG001", "value": "-6.33", "spread": "1.671"}]}]}, {"title": "2-hour postprandial proinsulin (n=93, 193)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.55", "spread": "4.200"}, {"groupId": "OG001", "value": "-4.20", "spread": "3.550"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Fasting Proinsulin-to-insulin Ratio and 2-hour Postprandial Proinsulin-to-insulin Ratio at Week 24", "description": "The fasting proinsulin-to-insulin ratio and 2-hour postprandial proinsulin-to-insulin ratio were measured during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data imputed using LOCF. Number of patients analyzed=patients with baseline and at least 1 post-baseline proinsulin-to-insulin ratio assessment during on-treatment period and 'n'= patients with baseline and at least 1 post-baseline assessment for the specific category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "199"}]}], "classes": [{"title": "Fasting proinsulin-to-insulin ratio (n=95, 199)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "0.049"}, {"groupId": "OG001", "value": "-0.13", "spread": "0.043"}]}]}, {"title": "2-hour postprandial ratio (n=92, 190)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.060"}, {"groupId": "OG001", "value": "0.16", "spread": "0.053"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting C-peptide and 2-hour Postprandial C-peptide at Week 24", "description": "The fasting C-peptide and the 2-hour postprandial C-peptide blood samples were drawn during a standardized meal challenge test (performed in selected sites). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "Subgroup for standardized meal test in mITT population. Missing data was imputed using LOCF. here. number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period and 'n' = patients with baseline and at least 1 post-baseline assessment for the specified category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "248"}]}], "classes": [{"title": "Fasting C-peptide (n=117, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.038"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.031"}]}]}, {"title": "2-hour postprandial C-peptide (n=119, 248)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "0.087"}, {"groupId": "OG001", "value": "-0.37", "spread": "0.072"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.5"}, {"groupId": "OG001", "value": "36.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "544"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.7"}, {"groupId": "OG001", "value": "19.3"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "554"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "14.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}, {"groupId": "OG001", "value": "570"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.6"}, {"groupId": "OG001", "value": "4.0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.The one patient in the placebo group who received Lixisenatide was analyzed in the Lixisenatide group", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 120 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "574"}]}], "classes": [{"title": "Symptomatic hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "127"}]}]}, {"title": "Severe symptomatic hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First dose of study drug up to 3 days after the last dose administration, for up to 120 weeks", "description": "Median exposure to study treatment was 617 and 610 days in placebo and lixisenatide treatment arms, respectively. The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered. The one patient in the placebo group who received Lixisenatide was analyzed in the Lixisenatide group", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo.", "seriousNumAffected": 35, "seriousNumAtRisk": 285, "otherNumAffected": 148, "otherNumAtRisk": 285}, {"id": "EG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide.", "seriousNumAffected": 58, "seriousNumAtRisk": 574, "otherNumAffected": 362, "otherNumAtRisk": 574}], "seriousEvents": [{"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Colitis herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Leptospirosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Brain neoplasm benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Glottis carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hepatic neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Rectosigmoid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Allergy to arthropod sting", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Schizophrenia simple", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Schizophrenia, paranoid type", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Essential tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Lacunar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "VIIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Cataract nuclear", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Vitreous haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Sudden hearing loss", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Aortic stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Hiccups", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Colonic polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Pancreatitis chronic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Reflux oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hepatitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Calculus urinary", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Adenomatous polyposis coli", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Blood calcitonin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "In-stent coronary artery restenosis", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Multiple injuries", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Muscle injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Periorbital haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 574}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 574}]}, {"term": "Coronary angioplasty", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 574}]}, {"term": "Coronary arterial stent insertion", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 574}]}, {"term": "Percutaneous coronary intervention", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 574}]}], "otherEvents": [{"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 574}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 58, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 91, "numAtRisk": 574}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 43, "numAtRisk": 574}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 55, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 140, "numAtRisk": 574}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 574}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 574}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 574}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 71, "numAtRisk": 574}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 574}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 161, "numAtRisk": 574}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 61, "numAtRisk": 574}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 574}]}, {"term": "Blood glucose decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 285}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 574}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-us@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}